The median OS was statistically significantly longer for nab-paclitaxel plus gemcitabine vs gemcitabine alone ( 8.7 vs 6.6 months , hazard ratio [ HR ] = 0.72 , 95 % confidence interval [ CI ] = 0.62 to 0.83 , P < .001 ) .